Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Sean Senn

Ilya Rachman

Vladimir Torchilin

Immix Biopharma, Inc.

MannKind Corporation develops and commercializes innovative therapeutic products and devices for people living with endocrine and orphan lung diseases.

MannKind Corporation

Immix Biopharma, Inc. (ImmixBio™) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases. Our lead asset, IMX-110, is currently in phase 1b/2a clinical trials for solid tumors in the United States and Australia. Our proprietary System Multi-Action RegulaTors SMARxT Tissue-Specific Platform produces drugs that accumulate at intended therapeutic sites at 3-5 times that of conventional medicines. Our TME Normalization™ Technology allows our drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the tumor micro-environment, or TME. We have uncovered fundamental biological systems that link oncology and inflammation. Our pipeline includes pre-clinical tissue-specific therapeutics to treat inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.

Mesa Verde Venture Partners

Immix Biopharma (Nasdaq: IMMX)

Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting

Read the press release here: https://loom.ly/1Pu09G0

#cancertreatment #biopharma #sciencenews

Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

Read the press release here: https://loom.ly/4PQGN9c

#science #biopharma #cancertreatment #multiplemyeloma #car-t

Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

Read the press release here: https://loom.ly/HCKoAzU

#cancertreatment #science #biopharma

Immix Biopharma is pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ 

Read more here: https://lnkd.in/emdDgvbQ

#science #cancertreatment #technology

Immix Biopharma's subsidiary Nexcella, Inc. 

Learn more about Nexcella, Inc.: https://nexcella.com/  

#biopharma #cancertreatment #science

Who founded Immix Biopharma?

Read more here: https://lnkd.in/enZ6FH3s 

#science #cancer #biopharma

Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference

#healthcare #science #biopharma

Dr. Suzanne Lentzsch Joins Immix Biopharma Scientific Advisory Board

Read the press release here: https://loom.ly/spWfYjU

#sciencenews #biopharma

FDA Orphan Drug Designation (“ODD”) qualifies NXC-201 for the following: 

Read the press release here: https://loom.ly/fwrLYNQ

#fda #science #cancer

U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma

Read the press release here: https://loom.ly/fwrLYNQ 

#science #biopharma #sciencenews

Metric
Company Name	Immix Biopharma, Inc.	MannKind Corporation
Symbol	IMMX
MSH ID	COM:IMMIXBIO	COM:VALERITAS
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	US	US
Stage
Employee Count	14
Website	immixbio.com	valeritas.com
LinkedIn	immix-biopharma
Founders

Metric
Market Cap	53.89M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:IMMIXBIO

Immix Biopharma, Inc.

Last Close

1.68

22/11 21:00

Market Cap

53.89M

Beta: -

Volume Today

249.22K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue